Encouraging Phase II data support share price rise for CymaBay

12 April 2018

Shares in CymaBay Therapeutics (Nasdaq: CBAY) leapt yesterday on news from a Phase II study of seladelpar in patients with primary biliary cholangitis (PBC).

The interim analysis of the trial into the orally-administered non-alcoholic steatohepatitis (NASH) candidate showed the drug “exhibits potent and sustained anti-cholestatic and anti-inflammatory efficacy over 26 weeks of administration.”

CymaBay said the drug was generally safe and well tolerated, with no transaminase elevation safety signal. Although there were six serious adverse events, none were deemed related to seladelpar.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK